rituximab + teniposide + cyclophosphamide + idarubicin + lomustine + prednisone

R-VICCP is a multi-agent chemoimmunotherapy regimen primarily evaluated for the treatment of Mantle Cell Lymphoma (MCL), particularly in elderly patients who are often ineligible for intensive high-dose chemotherapy and autologous stem cell transplantation. The regimen combines the targeted anti-CD20 monoclonal antibody rituximab with a backbone of five cytotoxic and supportive agents: teniposide (a podophyllotoxin derivative and topoisomerase II inhibitor), idarubicin (an anthracycline that intercalates DNA and inhibits topoisomerase II), cyclophosphamide and lomustine (alkylating agents that induce DNA cross-linking), and prednisone (a corticosteroid that induces apoptosis in lymphoid cells). This combination aims to provide synergistic anti-tumor activity by simultaneously targeting the CD20 surface antigen and multiple points of the DNA replication and repair machinery. While the regimen demonstrated efficacy in trials conducted by the Groupe d'Etude des Lymphomes de l'Adulte (GELA), it has largely been superseded by other rituximab-based regimens like R-CHOP or R-bendamustine in modern clinical practice.

Other names

R-VICCP regimenVICCP-R